| Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility NR Silvaggi, GE Boldt, MS Hixon, JP Kennedy, S Tzipori, KD Janda, ... Chemistry & biology 14 (5), 533-542, 2007 | 149 | 2007 |
| The mechanism of Class II, metal‐dependent aldolases WD Fessner, A Schneider, H Held, G Sinerius, C Walter, M Hixon, ... Angewandte Chemie International Edition in English 35 (19), 2219-2221, 1996 | 141 | 1996 |
| An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists LM Eubanks, MS Hixon, W Jin, S Hong, CM Clancy, WH Tepp, ... Proceedings of the National Academy of Sciences 104 (8), 2602-2607, 2007 | 136 | 2007 |
| Metabolomics-based discovery of diagnostic biomarkers for onchocerciasis JR Denery, AAK Nunes, MS Hixon, TJ Dickerson, KD Janda PLoS neglected tropical diseases 4 (10), e834, 2010 | 106 | 2010 |
| Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitors GE Boldt, JP Kennedy, MS Hixon, LA McAllister, JT Barbieri, S Tzipori, ... Journal of combinatorial chemistry 8 (4), 513-521, 2006 | 92 | 2006 |
| Calcium-dependent and-independent interfacial binding and catalysis of cytosolic group IV phospholipase A2 MS Hixon, A Ball, MH Gelb Biochemistry 37 (23), 8516-8526, 1998 | 85 | 1998 |
| NB2001, a novel antibacterial agent with broad-spectrum activity and enhanced potency against β-lactamase-producing strains Q Li, JY Lee, R Castillo, MS Hixon, C Pujol, VR Doppalapudi, ... Antimicrobial agents and chemotherapy 46 (5), 1262-1268, 2002 | 84 | 2002 |
| Onchocerca volvulus-neurotransmitter tyramine is a biomarker for river blindness D Globisch, AY Moreno, MS Hixon, AAK Nunes, JR Denery, S Specht, ... Proceedings of the National Academy of Sciences 110 (11), 4218-4223, 2013 | 71 | 2013 |
| Interfacial recognition by bee venom phospholipase A2: insights into nonelectrostatic molecular determinants by charge reversal mutagenesis F Ghomashchi, Y Lin, MS Hixon, BZ Yu, R Annand, MK Jain, MH Gelb Biochemistry 37 (19), 6697-6710, 1998 | 69 | 1998 |
| Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein D Van Egeren, A Novokhodko, M Stoddard, U Tran, B Zetter, M Rogers, ... PloS one 16 (4), e0250780, 2021 | 67 | 2021 |
| Botulinum neurotoxin A protease: discovery of natural product exosite inhibitors P Šilhár, K Čapková, NT Salzameda, JT Barbieri, MS Hixon, KD Janda Journal of the American Chemical Society 132 (9), 2868-2869, 2010 | 62 | 2010 |
| Identification of a natural product antagonist against the botulinum neurotoxin light chain protease LM Eubanks, P Šilhár, NT Salzameda, JS Zakhari, F Xiaochuan, ... ACS medicinal chemistry letters 1 (6), 268-272, 2010 | 57 | 2010 |
| Catalytic antibody degradation of ghrelin increases whole-body metabolic rate and reduces refeeding in fasting mice AV Mayorov, N Amara, JY Chang, JA Moss, MS Hixon, DI Ruiz, ... Proceedings of the National Academy of Sciences 105 (45), 17487-17492, 2008 | 57 | 2008 |
| Monoclonal antibodies for combating synthetic opioid intoxication LC Smith, PT Bremer, CS Hwang, B Zhou, B Ellis, MS Hixon, KD Janda Journal of the American Chemical Society 141 (26), 10489-10503, 2019 | 50 | 2019 |
| Probing Active Cocaine Vaccination Performance through Catalytic and Noncatalytic Hapten Design X Cai, T Whitfield, MS Hixon, Y Grant, GF Koob, KD Janda Journal of medicinal chemistry 56 (9), 9701-3709, 2013 | 47 | 2013 |
| Rapid Determination of the Specificity Constant of Irreversible Inhibitors (kinact/KI) by Means of an Endpoint Competition Assay I Miyahisa, T Sameshima, MS Hixon Angewandte Chemie 127 (47), 14305-14308, 2015 | 46 | 2015 |
| Discovery of acetylcholinesterase peripheral anionic site ligands through computational refinement of a directed library TJ Dickerson, Beuscher, CJ Rogers, MS Hixon, N Yamamoto, Y Xu, ... Biochemistry 44 (45), 14845-14853, 2005 | 46 | 2005 |
| Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism H Iwata, S Imamura, A Hori, MS Hixon, H Kimura, H Miki Biochemistry 50 (5), 738-751, 2011 | 42 | 2011 |
| Toward the discovery of potent inhibitors of botulinum neurotoxin A: development of a robust LC MS based assay operational from low to subnanomolar enzyme concentrations K Čapková, MS Hixon, LA McAllister, KD Janda Chemical communications, 3525-3527, 2008 | 41 | 2008 |
| Discovery of novel benzo [b][1, 4] oxazin-3 (4H)-ones as poly (ADP-ribose) polymerase inhibitors AR Gangloff, J Brown, R De Jong, DR Dougan, CE Grimshaw, M Hixon, ... Bioorganic & medicinal chemistry letters 23 (16), 4501-4505, 2013 | 37 | 2013 |
John SchlossVerified email at otosciencelabs.com
